Compare Chevron Corp (CVX) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Illumina, Inc. — how do they compare? Chevron Corp trades at $211.98 (market cap $414.98B), while Illumina, Inc. trades at $278.17 (market cap $39.95B). The key difference: Chevron Corp is far larger — about 10.4× Illumina, Inc.'s market cap, and Chevron Corp pays a 3.37% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Chevron Corp for 101 Days and Illumina, Inc. for 83 Days on average.
| CVX | ILMN | |
|---|---|---|
Market Cap | $414.98B | $39.95B |
Volume | 7,575,112 | 3,169,503 |
Sector | Energy | Health |
52-Week High | $217.73 | $293.69 |
52-Week Low | $146.72 | $91.00 |
Typical Hold Time | 101 Days | 83 Days |
Enterprise Value | $443.52B | $41.31B |
Dividend Yield | 3.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $211.605, up 3.13% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock is supported by robust cash flow from operations of $33.94B in 2025 and a dividend of $1.78 per share. However, revenue and net income have declined from 2022 peaks, with 2025 revenue at $184.43B and net income at $12.30B. Analyst consensus is bullish with a $208.31 price target, though geopolitical tensions and oil price volatility pose risks.
The outlook for CVX is cautiously optimistic, driven by high oil prices and strategic investments like the $13.8B Argentina project. Investment opportunities include a solid dividend yield and potential upside from production growth. Key risks are exposure to fluctuating oil prices, geopolitical instability affecting supply chains, and declining profit margins. Investors should weigh strong cash generation against cyclical industry pressures.
ILMN trades at $264.40, down 1.25% on the day, but remains near its recent 52-week high of $278.99 (Defense World, 2026-10-01). The stock has surged 94.9% year-to-date (Zacks Investment Research, 2026-09-24), supported by strong earnings beats in recent quarters and a bullish technical trend. Fundamentals show a significant turnaround, with 2025 net income reaching $850 million after prior losses, though valuation ratios like a P/E of 49.36 are elevated. The pending inclusion in the S&P 500 (PRNewsWire, 2026-09-04) adds a positive catalyst.
The outlook is positive, driven by sequencing growth, AI integration in genomics, and improved profitability. However, risks include high valuation sensitivity, cost volatility, and competitive pressures in the life sciences sector. Analyst consensus is bullish with a 54% buy rating, but the average price target of $241 suggests limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
